Evidence map›Paper›PMID 22227183›Full record

Trial reportJournal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation2012

Association of 1,25-dihydroxyvitamin D levels with physical performance and thigh muscle cross-sectional area in chronic kidney disease stage 3 and 4.

Patricia L Gordon, Julie W Doyle, Kirsten L Johansen

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Frailty in Kidney Disease: A Comprehensive Review to Advance Its Clinical and Research Applications.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Review
  13. Review
  14. [Frailty in renal diseases].Zeitschrift fur Gerontologie und Geriatrie · 2021
    Review
  15. Article
  16. Article
  17. Vitamin D, a modulator of musculoskeletal health in chronic kidney disease.Journal of cachexia, sarcopenia and muscle · 2017
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Patricia L GordonDivision of Nephrology, Department of Medicine, University of California, San Francisco, California 94121, USA. patricia.gordon@ucsf.edu
Julie W Doyle
Kirsten L Johansen
University of California, San Francisco · USSan Francisco VA Medical Center · US

Funding

Prevalence and Impact of Frailty among Dialysis PatientsK24DK085153 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHANSEN, KIRSTEN L. · 2010 to 2021
$1.5M
NIDDK NIH HHS K24 DK085153
6 · The paper itself

Abstract

backgroundDeclines in 1,25-dihydroxyvitamin D (1,25(OH)₂D) levels and physical functioning follow the course of chronic kidney disease (CKD). Although the molecular actions of vitamin D in skeletal muscle are well known, and muscle weakness and atrophy are observed in vitamin D-deficient states, there is little information regarding vitamin D and muscle function and size in CKD.

objectiveTo examine associations of vitamin D with physical performance (PF) and muscle size.

designCross-sectional.

settingCKD clinic. SUBJECTS: Twenty-six patients (61 ± 13 years, 92% men) with CKD stage 3 or 4.

main outcome measuresGait speed, 6-minute walk, sit-to-stand time, 1-legged balance, and thigh muscle cross-sectional area (MCSA), measured by magnetic resonance imaging (MRI).

resultsOverall, 73% were 25-hydroxyvitamin D (25(OH)D) deficient (n = 10) or insufficient (n = 9) (Kidney Disease Outcomes Quality Initiative guidelines). 25(OH)D level was associated with normal gait speed only (r = 0.41, P = .04). Normal and fast gait speed, the distance walked in 6 minutes, and sit-to-stand time were best explained by 1,25(OH)₂D and body mass index (P < .05 for all) and 1-legged stand by 1,25(OH)₂D (r = 0.40, P < .05) only. There were no associations of age, estimated glomerular filtration rate (eGFR), intact parathyroid hormone (iPTH), or albumin with any PF measures. MCSA was associated with eGFR (r = 0.54, P < .01) only. Variance in MCSA was best explained by a model containing 1,25(OH)₂D, plasma Ca²⁺, and daily physical activity (by accelerometry) (P < .05 for all). Once these variables were in the model, there was no contribution of eGFR.

conclusionThese results suggest that 1,25(OH)₂D is a determinant of PF and muscle size in patients with stage 3 and 4 CKD.

Indexed as

Anatomy, Cross-SectionalMotor ActivityAdultAgedAged, 80 and overCalciumDouble-Blind MethodFemaleHumansKidney Failure, ChronicMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisMuscle, SkeletalParathyroid Hormone1,25-dihydroxyvitamin DCalciumParathyroid HormoneSerum AlbuminVitamin D

Identifiers

PMID22227183
PMCPMC4815913
OpenAlexW2150999319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.